Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,006 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The interplay between alterations in esophageal microbiota associated with Th17 immune response and impaired LC20 phosphorylation in achalasia.
Ikeda H, Ihara E, Takeya K, Mukai K, Onimaru M, Ouchida K, Hata Y, Bai X, Tanaka Y, Sasaki T, Saito F, Eto M, Nakayama J, Oda Y, Nakamura M, Inoue H, Ogawa Y. Ikeda H, et al. Among authors: eto m. J Gastroenterol. 2024 May;59(5):361-375. doi: 10.1007/s00535-024-02088-w. Epub 2024 Mar 12. J Gastroenterol. 2024. PMID: 38472375
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Grünwald V, et al. Among authors: eto m. Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35288. Online ahead of print. Int J Cancer. 2024. PMID: 39739622
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: eto m. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
A Real-Time Web-Based Intervention with a Multicomponent Group-Based Program for Older Adults: Single-Arm Feasibility Study.
Nakada T, Kurotani K, Kozawa T, Seino S, Murota S, Eto M, Shimasawa J, Shimizu Y, Tsurugano S, Katsukawa F, Sakamoto K, Washizaki H, Ishigaki Y, Sakamoto M, Takadama K, Yanai K, Matsuo O, Kameue C, Suzuki H, Ohkawara K. Nakada T, et al. Among authors: eto m. Healthcare (Basel). 2024 Nov 26;12(23):2365. doi: 10.3390/healthcare12232365. Healthcare (Basel). 2024. PMID: 39684987 Free PMC article.
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK. Motzer RJ, et al. Among authors: eto m. Ann Oncol. 2024 Dec 11:S0923-7534(24)04978-0. doi: 10.1016/j.annonc.2024.12.003. Online ahead of print. Ann Oncol. 2024. PMID: 39672382 Free article.
1,006 results